Krystal Biotech earnings and revenue momentum come into focus

Krystal Biotech (KRYS) is back in the spotlight after reporting second quarter 2026 results that included net income of US$54.77 million and basic earnings per share from continuing operations of US$1.85.

The recent earnings update and 24% net product revenue growth for VYJUVEK came after a strong run, with Krystal Biotech posting a year to date share price return of 34.81% and a 1 year total shareholder return of 122.89%. However, the 30 day share price return declined 8.41%, hinting at some cooling in short term momentum compared with its very large 5 year total shareholder return of 509.97%.

If this kind of earnings driven move has your attention, it could be a good moment to look at other companies in the sector through a curated set of 43 healthcare AI stocks.

Krystal Biotech now trades about 15% below the average analyst price target and at a much larger discount to one estimate of intrinsic value, even after its strong run. Is the market’s recent caution sensible or excessive?

Most Popular Narrative: 8% Undervalued

Krystal Biotech’s most followed narrative pegs fair value at about $361.67, compared with the last close at $332.86. That gap is driving the current debate on whether recent earnings justify a higher price, especially with a 7.11% discount rate incorporated into the model.

The expansion of Krystal's pipeline, including imminent and near-term clinical readouts in lung disease (AATD, CF), ophthalmology, oncology (NSCLC), and aesthetics, leverages increased R&D productivity, which could drive future revenue growth and diversify earnings beyond a single product.

Favorable dynamics in global healthcare, such as greater willingness to reimburse curative, high-value genetic therapies and broadening awareness due to successful launches and patient outcomes, should support sustainable long-term revenue growth and premium pricing, boosting revenue visibility and potentially net margins.

Want to see what sits behind that pipeline driven story for Krystal Biotech? The narrative leans on aggressive top line expansion, stickier margins, and a future earnings multiple that assumes sustained demand. Investors may be curious which specific growth and profitability paths would need to play out to support that fair value.

Result: Fair Value of $361.67 (UNDERVALUED)

However, Krystal Biotech’s story still hinges on VYJUVEK concentration risk and clinical readouts for assets like KB801 and KB407 that could reset expectations quickly.

Another View on Krystal Biotech’s valuation

The SWS DCF model values Krystal Biotech at about $1,044.39 per share, compared with the current price of $332.86. That is a 68.1% gap that points to a very different story from the analyst fair value of $361.67. Which set of assumptions do you find more realistic for the long run?

Next Steps

With both enthusiasm and caution running through the Krystal Biotech story, it makes sense to move quickly and check the underlying data yourself. To understand the balance of potential upside and the issues investors are watching, take a closer look at the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Krystal Biotech?

Do not stop with Krystal Biotech. Use the Simply Wall Street Screener to surface fresh ideas that fit your style before others move first.

• Target dependable income by scanning for companies in the 9 dividend fortresses that may suit a yield focused approach.
• Zero in on potential value opportunities through the 49 high quality undervalued stocks and see which stocks align with your return and risk preferences.
• Reduce potential downside by reviewing companies in the 85 resilient stocks with low risk scores that score strongly on financial resilience.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.